To investigate the mechanism of action of the potent antiviral compound PD 404182, three novel photoaffinity probes equipped with a biotin or alkyne indicator were designed and synthesized based on previous structure-activity relationship studies. These probes retained the potent anti-HIV activity of the original pyrimidobenzothiazine derivatives. In photoaffinity labeling studies using HIV-1-infected H9 cells (H9IIIB), eight potential proteins were observed to bind PD 404182.
Introduction
3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) (1) 1-3 is a potent antiviral agent against the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV) ( Fig. 1) . 4, 5 In structure-activity relationship (SAR) studies 5, 6 of compound 1 using a series of facile synthetic procedures, 7, 8 we identified several derivatives 24 that exhibited two-or three-fold more potent anti-HIV activity than compound 1. The comparative time of drug addition study using standard anti-HIV agents demonstrated that compound 1 showed a similar antiviral profile against HIV-1 IIIB infection with that of DS 5000 (adsorption inhibitor) 9 and enfuvirtide (fusion inhibitor), 10 indicating that compound 1 impaired virus replication at the early-stage of HIV infection. 5 Additionally, the antiviral activities of compound 1 against multiple HIV clades suggest that the target molecule of compound 1 is not chemokine receptors (CC chemokine receptor type 5 11 or CXC chemokine receptor type 4 12 ). 5 Recently, the virucidal effects of compound 1 against HCV, HIV and the simian immunodeficiency virus have also been reported. 13 However, the mode of action and mechanism of antiviral activity of compound 1 has not yet been fully elucidated.
Photoaffinity labeling is an efficient approach to identify the target protein(s) of biologically active molecules. 14 In modern drug discovery, there have been a number of successful examples that have determined the target molecules and identified the binding site through the formation of a covalent bond between the ligand and the specific protein. 15 In general, photoaffinity probes contain three functional groups: a bioactive scaffold, a photoreactive group and an indicator group. A biotin-tag is widely employed as an indicator because biotinylated proteins can be detected and isolated by several immunological methods or through a biotin-avidin interaction. 16 A terminal alkyne is an alternative indicator for Huisgen cycloaddition-mediated conjugation with various azide-modified reporters, such as fluorescent-azide and biotin-azide after the crosslinking reaction onto the target protein(s). 17 In this article, the design and synthesis of biotin-or alkyne-conjugated photoaffinity probes based on previous SAR studies and its application for photoaffinity labeling studies are described.
Conclusions
In conclusion, we have designed and synthesized novel photoaffinity probes of antiviral PD 404182 with photoreactive benzophenone, and biotin or alkyne indicators. The probes exhibited equipotent or slightly less potent anti-HIV activities when compared with the activity of the parent compound 1. Preliminary photoaffinity labeling experiments suggest that these probes could be useful in the identification of a potential target protein(s), the binding site on the target protein(s) and the mechanism(s) of action of PD 404182 derivatives.
Experimental

Synthesis
General methods.
1 H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer.
Chemical shifts are reported in δ (ppm) relative to Me 4 Si (CDCl 3 ) or DMSO (DMSO-d 6 ) as internal standards. 13 C NMR spectra were referenced to the residual solvent signal. Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer. Melting points were measured by a hot stage melting point apparatus (uncorrected). For flash chromatography, Wakogel C-300E (Wako) or aluminum oxide 90 standardized (Merck) were employed. For preparative TLC, TLC silica gel 60 F 254 (Merck) or TLC aluminum oxide 60 F 254 basic (Merck) were employed. For analytical HPLC, a Cosmosil 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque, Inc., Kyoto, Japan) was employed with a linear gradient of CH 3 CN containing 0.1% (v/v) NH 3 at a flow rate of 1 mL/min on a Shimadzu LC-10ADvp (Shimadzu Corp., Ltd, Kyoto, Japan), and eluting products were detected by UV at 254 nm. Preparative HPLC was performed using a COSMOSIL 5C18-ARII column (20 × 250 mm, Nacalai Tesque Inc.) with a linear gradient of MeCN containing 0.1 % (v/v) NH 3 at a flow rate of 8 mL/min on Shimadzu LC-6AD (Shimadzu corporation, Ltd). The purity of the compounds 6-8 was determined by HPLC analysis as >95%.
4-[(tert-Butyldiphenylsilyloxy)methyl]-N-methoxy-N-methylbenzamide (10).
To a mixture of 4-(hydroxymethyl)benzoic acid 9 (4.6 g, 30.0 mmol), N,O-dimethylhydroxylamine hydrochloride (14.6 g, 150.0 mmol), Et 3 N (21.7 mL, 150.0 mmol) in DMF (300 mL) were added EDC·HCl (11.5 g, 60.0 mmol) and HOBt·H 2 O (9.2 g, 60.0 mmol). After being stirred at rt overnight, solvent was evaporated. The residue was dissolved in EtOAc, and washed with 1 N HCl, satd NaHCO 3 , brine, and dried over MgSO 4 
4-[(tert-Butyldiphenylsilyloxy)methyl]-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzophenone (11).
To a solution of 1,4-dibromobenzene (3.13 g, 13.3 mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.80 mL, 13.8 mmol) in anhydrous THF (60 mL) was added t-BuLi (19. After concentration, the residue was purified by silica gel chromatography with n-hexane/EtOAc 
9-{4-[4-(tert-Butyldiphenylsilyloxy)methyl]benzoylphenyl}-3,4-dihydro-N-(p-methoxybenzyl)-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (13).
Pd(PPh 3 ) 4 (32.8 mg, 4 mol%) and PdCl 2 (dppf)·CH 2 Cl 2 (17.4 mg, 3 mol %) were added to a solution of 12 (296.2 mg, 0.71 mmol) and 11 (409.4 mg, 0.71 mmol) in toluene (7.1 mL)-EtOH (4.3 mL)-1 M aq. K 2 CO 3 (7.1 mL). After being stirred at reflux for 1 h, the mixture was extracted with CHCl 3 . The extract was dried over MgSO 4 and concentrated. The residue was purified by flash chromatography over aluminum oxide with n-hexane/EtOAc (1:0 to 9:1) to give the title compound 
N-(2-[2-{2-(2-Aminoethoxy)ethoxy}ethoxy]ethyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-1Hthieno[3,4-d]imidazol-4-yl]pentanamide (15) .
To the solution of 14 (116.0 mg, 0.26 mmol) in MeOH (2.0 mL) was added 10% Pd-C (wetted with ca. 55% water, 160.0 mg). After being stirred at rt overnight under H 2 atmosphere, the mixture was filtered through a celite pad and concentrated. The crude product was used for the next step without further purification.
4-(4-{6-[(4-Methoxybenzyl)imino]-2,3,4,6-tetrahydrobenzo[e]pyrimido[1,2-c][1,3]thiazin-9-yl}benzoyl)benzyl {13-oxo-17-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]-
imidazol-4-yl]-3,6,9-trioxa-12-azaheptadecyl}carbamate (17).
To a solution of 13 (157.2 mg, 0.20 mmol) in THF (2.0 mL) was added TBAF in THF (0.50 mL, 0.50 mmol). After being stirred at rt overnight, the reaction mixture was quenched with satd NH 4 Cl.
The whole was extracted with CHCl 3 and dried over MgSO 4 . After concentration, the residue was subjected to flash column chromatography over aluminum oxide with n-hexane/EtOAc (5:1 to 0:1) to give the desilylated compound. To a solution of the resulting compound in CH 2 Cl 2 (6.0 mL) were 1.9. N-[9-Bromo-1'-(4-methoxybenzyl)-2H-spiro(benzo[e]pyrimido[1,2-c][1,3]thiazine-3,4'- 
4.
piperidin)-6(4H)-ylidene]-1-(4-methoxyphenyl)methanamine (19).
By a procedure identical with that described for synthesis of 12 from 2a, the imine 18 (274.3 
N-[9-Bromo-2H-spiro(benzo[e]pyrimido[1,2-c][1,3]thiazine-3,4'-piperidin)-6(4H)ylidene]-1-(4-methoxyphenyl)methanamine (20).
To a solution of 19 (60.6 mg, 0.10 mmol) in CH 2 Cl 2 (0.5 mL) were added Et 3 N (28.9 μL, 0.20 mmol) and 1-chloroethyl chloroformate (21.8 μL, 0.20 mmol) at 0 °C under an Ar atmosphere.
After being stirred at the same temperature for 30 min, the reaction mixture was concentrated. The residue was dissolved in MeOH (2.0 mL). After being stirred under reflux for 10 min, the reaction mixture was concentrated. The residue was dissolved in CHCl 3 , and was washed with satd NaHCO 3 , brine, and dried over MgSO 4 . After concentration, the crude product was used for the next step without further purification. To a solution of 21 20 
4-[4-(Hydroxymethyl)benzoyl]benzyl {13-oxo-17-[(3aS,4S,6aR)-2-oxohexahydro-1Hthieno[3,4-d]imidazol-4-yl]-3,6,9-trioxa-12-azaheptadecyl}carbamate (24).
To a solution of 23 (383.0 mg, 0.41 mmol) in THF (8.2 mL) was added HF-pyridine (617.7 μL, 0.55 mmol) at 0 °C. After being stirred at rt overnight, the reaction was quenched with satd NaHCO 3 . The whole was extracted with CHCl 3 , and washed with water and brine, and dried over 1.14. 4-(4-{3,17-Dioxo-21-[(3aS,4S,6aR) 1.15. N-(tert-Butyl)-9-{4-[4-(tert-butyldiphenylsilyloxy)methyl]benzoylphenyl}-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3] benzothiazin-6-imine (28).
Compound 27 (2.17 g, 6.17 mmol) was subjected to the general cross-coupling procedure as described for the synthesis of 13 to give the title compound 28 as colorless solid (3.16 g, 71%): mp N-(tert-Butyl)-3,4-dihydro-9-[4-(4-propargyloxymethyl) 1.17. 3,4-Dihydro-9-[4-(4-propargyloxymethyl)benzoylphenyl]-2H,6H-pyrimido[1,2-c][1,3] benzothiazin-6-imine (8).
Using a procedure identical with that described for synthesis of 6 from 17, the imine 29 (42.8 mg, 0.08 mmol) was allowed to react under reflux for 1 h with TFA (2.0 mL) and MS4Å (300 mg).
Purification by flash chromatography over aluminum oxide with n-hexane/EtOAc (9:1 to 1:1) gave the title compound 
Determination of anti-HIV activity.
The sensitivity of HIV-1 IIIB strain was determined by the MAGI assay. The target cells 
Photoaffinity labeling experiments using HIV-1-infected H9 cells (H9IIIB).
1 L of probe 6 or 7 (10 mM solution in DMSO) was added to H9 cells chronically infected with HIV-1 (H9IIIB) in D-MEM with 10% fetal bovine serum (500 L, 0.5 × 10 6 cells). For the competitive evaluation (Fig. 3 , lane C), 2 L of compound 3a (10 mM solution in DMSO) was also added. The cells were incubated at 37 °C for 1 h. Then the cells were photolabeled by irradiation by UV (MUV-202U, Moritex Co., Japan) at room temperature for 1 min at a distance of 3 cm through a longpass filter (LU0300, Asahi spectra Co.). The mixture was centrifuged at 200 × g for 5 min and the supernatant was removed. The cells were washed with PBS once and were lysed in RIPA buffer containing 1% protease inhibitor cocktail (Nacalai Tesque, Inc., Japan) at 4 °C for 30 min.
After centrifugation at 16500 × g for 15 min, the supernatant was used for the next experiment.
NeutrAvidin agarose beads (50 L, Thermo), which were equilibrated with RIPA buffer, were treated with the supernatant containing 180 g of proteins and were incubated at 4 °C for 1 h. The beads were then centrifuged at 9,100 × g for 30 sec and washed with RIPA buffer (repeated three times 
